EUVIMEDOpdag EUVIMED
Crossref

Quantitative determination of plasma cabozantinib concentration using HPLC–UV and its application to patients with renal cell carcinoma

Shinichi Maruyama, Masaru Kato iD, Tatsuru Hiraga, Masaru Ishida, Hiroshi Kanno

Biomedical Chromatography · 2023

DOI: 10.1002/bmc.5599 ↗

At a glance

Journal article in Biomedical Chromatography, 2023. Written by Shinichi Maruyama and 4 co-authors. Institution: Department of Pharmacy, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan. Major MEDLINE topics: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Cited 7 times so far (Crossref); 15 references. Funded by: Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cabozantinib is an oral small‐molecule tyrosine kinase inhibitor that has become a standard of care for advanced renal cell carcinoma (RCC). However, cabozantinib is associated with a high rate of adverse events. Therefore, individualised cabozantinib administration and monitoring could help maximise its therapeutic efficacy and avoid serious adverse events. This study developed and validated a method to determine cabozantinib concentration in plasma using HPLC–UV. Sorafenib, an internal standard, was added to the plasma sample containing cabozantinib. A calibration curve for cabozantinib showed good linearity ( R 2 = 1.00), between 25 and 4,000 ng/ml. The recovery rate was above 92.1%, and the intra‐ and inter‐day coefficients of variation were smaller than 5.2 and 6.8%, respectively. Then, we applied the method for monitoring cabozantinib blood levels in three patients with advanced RCC who were taking cabozantinib at a dose of 20, 40 or 60 mg/day. Grade 3 adverse events were more likely to occur in patients with high dosing and blood level of cabozantinib. Owing to its simplicity, the developed method can be used in general hospitals, and is expected to help maximise drug efficacy and minimise serious adverse events in many patients with RCC undergoing cabozantinib treatment.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic AgentsHumansChromatography, High Pressure LiquidAnilidesPyridines

Author keywords

HPLCcabozantinibhuman plasmatherapeutic drug monitoring

Substances

Antineoplastic AgentsAnilidescabozantinibPyridines

Authors and institutions

  • Department of Pharmacy, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan.
  • Division of Bioanalytical Chemistry, Graduate School of Pharmacy, Tokyo, Japan.
  • Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan.

ORCID profiles: Masaru Kato

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Maruyama, S., Kato, M., Hiraga, T., Ishida, M., & Kanno, H. (2023). Quantitative determination of plasma cabozantinib concentration using HPLC–UV and its application to patients with renal cell carcinoma. Biomedical Chromatography. https://doi.org/10.1002/bmc.5599

Vancouver

Maruyama S, Kato M, Hiraga T, Ishida M, Kanno H. Quantitative determination of plasma cabozantinib concentration using HPLC–UV and its application to patients with renal cell carcinoma. Biomedical Chromatography. 2023. doi:10.1002/bmc.5599

BibTeX
@article{Maruyama2023,
  author = {Maruyama, Shinichi and Kato, Masaru and Hiraga, Tatsuru and Ishida, Masaru and Kanno, Hiroshi},
  title = {Quantitative determination of plasma cabozantinib concentration using HPLC–UV and its application to patients with renal cell carcinoma},
  journal = {Biomedical Chromatography},
  year = {2023},
  doi = {10.1002/bmc.5599}
}
Start for free →